6291-10-7

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyridinecarboxylic acid, 2-chloro-6-ethoxyis used as a key intermediate in the synthesis of various drugs and pharmaceutical products. Its unique molecular structure with chloro and ethoxy functional groups allows for versatile chemical reactions and modifications, enabling the development of new and effective medications.
Used in Organic Synthesis:
4-Pyridinecarboxylic acid, 2-chloro-6-ethoxyserves as a valuable building block in organic synthesis, providing a platform for the creation of a wide range of organic molecules. Its reactivity and functional groups make it suitable for various synthetic routes, contributing to the advancement of organic chemistry.
Used in Chemical Research:
4-Pyridinecarboxylic acid, 2-chloro-6-ethoxyis also employed in chemical research to study the properties and reactivity of pyridinecarboxylic acid derivatives. Its unique structure allows researchers to explore new reaction mechanisms, investigate the influence of functional groups on chemical behavior, and develop novel synthetic methodologies.

InChI:InChI=1/C8H8ClNO3/c1-2-13-7-4-5(8(11)12)3-6(9)10-7/h3-4H,2H2,1H3,(H,11,12)

Upstream product

• 141-52-6 sodium ethanolate 
• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 
• 64-17-5 ethanol 

Downstream Products

• 1370448-69-3 2-(4-(tert-butoxycarbonyl)phenyl)-6-ethoxyisonicotinic acid 
• 91940-86-2 2-ethoxyisonicotinic acid 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer

5-Fluorouracil (5-FU) and its prodrugs are the essential clinical drugs for colorectal cancer (CRC) treatment. However, the drug resistance of 5-FU has caused high mortality of CRC patients. Thus, it is urgent to develop reversal agents of 5-FU resistance. Sphingosine-1-phosphate receptor 2 (S1PR2) was proved to be a potential target for reversing 5-FU resistance, but the activity of known S1PR2 antagonists JTE-013 were weak in 5-FU-resistant cell lines. To develop more potent S1PR2 antagonists to treat 5-FU-resistant cancer, a series of JTE-013 derivatives were designed and synthesized. The most promising compound 40 could markedly reverse the resistance in 5-FU-resistant HCT116 cells and 5-FU-resistant SW620 cells via inhibiting the expression of dihydropyrimidine dehydrogenase (DPD). The key was that compound 40 with improved pharmacokinetic properties significantly increased the inhibitory rate of 5-FU in the SW620/5-FU cells xenograft model with no observable toxicity by inhibiting the expression of DPD in tumor and liver tissues. Altogether, these results suggest that compound 40 may be a promising drug candidate to reverse 5-FU resistance in the treatment of CRC.

N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS

The invention provides a compound of Formula (I) Z N N O N O A1R2 R1 R3R 3 L A 2 (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3,Z, A1, L and A 5 2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.